Lestaurtinib, JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor (ab142107)
- Datasheet
- References (1)
Overview
-
Product name
Lestaurtinib, JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor -
Description
Potent JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor -
Biological description
Potent JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor (IC50 values are 0.9, 3 and 25 nM respectively). Antiproliferative effects in vitro. Antileukemic agent in vivo. Orally active. -
Purity
> 98% -
CAS Number
111358-88-4 -
Chemical structure
Properties
-
Chemical name
(9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one -
Molecular weight
439.46 -
Molecular formula
C26H21N3O4 -
PubChem identifier
126565 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 10 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O -
Source
Synthetic
-
Research areas
References
This product has been referenced in:
- Hexner EO et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111:5663-71 (2008). Read more (PubMed: 17984313) »
- Weisel KC et al. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann N Y Acad Sci 1106:190-6 (2007). Read more (PubMed: 17442779) »
- Miknyoczki SJ et al. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann N Y Acad Sci 880:252-62 (1999). Read more (PubMed: 10415871) »
